| Literature DB >> 34172511 |
Elena Nikiphorou1,2,3, Pedro D Carvalho4,5, Annelies Boonen6,7, Bruno Fautrel8, Pascal Richette9, Pedro M Machado10,11,12, Desirée van der Heijde13, Robert Landewé14,15, Sofia Ramiro13,14.
Abstract
OBJECTIVES: To investigate the occurrence of sick leave (SL) and the impact of clinical and socioeconomic factors on SL in early axial spondyloarthritis (axSpA).Entities:
Keywords: ankylosing; epidemiology; inflammation; spondylitis
Year: 2021 PMID: 34172511 PMCID: PMC8237733 DOI: 10.1136/rmdopen-2021-001685
Source DB: PubMed Journal: RMD Open ISSN: 2056-5933
Figure 1Distribution of first and recurrent sick leave episodes over time in the study population. SL, sick leave. 1Censored due to unemployment/retirement/housework. 2Censored due to work disability.
Baseline characteristics of patients at risk of sick leave and for those with ‘Ever’ and ‘Never’ sick leave during the 5-year follow-up
| Baseline variables | At risk of sick leave | Ever sick leave | Never sick leave | P value* |
| Total N=620 | Total N=43 | Total N=577 | ||
| Age, years | 33.4 (8.6) | 36.8 (8.3) | 33.2 (8.6) | 0.007 |
| Male gender | 288, 47% | 11, 26% | 277, 48% | 0.004 |
| Caucasian ethnicity | 561, 91% | 38, 88% | 523, 91% | 0.625 |
| Higher education | 387, 63% | 16, 38% | 371, 64% | 0.001 |
| Missing values (%) | 2 (0.3) | 1 (2.3) | 1 (0.2) | |
| Blue-collar profession | 88, 16% | 7, 18% | 81, 16% | 0.839 |
| Missing values (%) | 82 (13.2) | 3 (7.0) | 79 (13.7) | |
| Married/In couple | 388, 63% | 33, 81% | 355, 62% | 0.016 |
| Missing values (%) | 3 (0.5) | 2 (4.6) | 1 (0.2) | |
| Parental status, number of children | 0.254 | |||
| 0 | 272, 45% | 13, 33% | 259, 46% | |
| 1 | 111, 18% | 12, 30% | 99, 18% | |
| 2 | 148, 25% | 12, 30% | 136, 24% | |
| 3 | 57, 9% | 2, 5% | 55, 10% | |
| 4 | 9, 1% | 1, 3% | 8, 1% | |
| 5 | 6, 1% | – | 6, 1% | |
| 6 | 1, 0% | – | 1, 0% | |
| Missing values (%) | 16 (2.6) | 3 (7.0) | 13 (2.3) | |
| Smoking, current | 217, 35% | 24, 56% | 193, 34% | 0.003 |
| Missing values (%) | 4 (0.6) | 0 (0.0) | 4 (0.7) | |
| HLA-B27 positivity | 368, 60% | 20, 47% | 348, 60% | 0.073 |
| Missing values (%) | 1 (0.2) | 0 (0.0) | 1 (0.2) | |
| Symptom duration, years | 1.5 (0.9) | 1.6 (0.9) | 1.5 (0.9) | 0.420 |
| Missing values (%) | 1 (0.2) | 0 (0.0) | 1 (0.2) | |
| ASDAS-CRP | 2.6 (0.9) | 2.8 (0.8) | 2.6 (0.9) | 0.064 |
| Missing values (%) | 28 (4.5) | 4 (9.3) | 24 (5.2) | |
| Elevated CRP (>6 mg/L) | 163, 27% | 10, 24% | 153, 27% | 0.612 |
| Missing values (%) | 20 (3.2) | 1 (2.3) | 19 (3.3) | |
| CRP, mg/L | 7.6 (13.5) | 5.9 (8.6) | 7.8 (13.8) | 0.338 |
| Missing values (%) | 20 (3.2) | 1 (2.3) | 19 (3.3) | |
| BASDAI, 0–10 | 4.3 (2.0) | 5.0 (2.0) | 4.3 (2.0) | 0.009 |
| Missing values (%) | 3 (0.5) | 2 (4.7) | 1 (0.2) | |
| BASFI, 0–10 | 2.9 (2.2) | 3.8 (2.2) | 2.8 (2.2) | 0.003 |
| Missing values (%) | 6 (1.0) | 1 (2.3) | 5 (0.9) | |
| BASMI, 0–10 | 2.4 (0.9) | 2.8 (0.9) | 2.4 (0.9) | 0.001 |
| Missing values (%) | 53 (8.5) | 3 (7.0) | 50 (8.7) | |
| History of uveitis | 57, 9% | 2, 5% | 55, 10% | 0.285 |
| History of psoriasis | 109, 18% | 7, 16% | 102, 18% | 0.816 |
| History of IBD | 32, 5% | 2, 5% | 30, 5% | 0.875 |
| History of peripheral arthritis | 40, 7% | 3, 7% | 37, 6% | 0.887 |
| Missing values (%) | 1 (0.2) | 0 (0.0) | 1 (0.2) | |
| Comorbidity count, 0–4 | 0.6 (0.6) | 0.7 (0.5) | 0.6 (0.6) | 0.190 |
| Missing values (%) | 9 (1.5) | 3 (6.8) | 6 (1.0) | |
| SIJ MRI, SPARCC score, 0–72 | 3.1 (6.6) | 3.1 (6.6) | 3.1 (6.6) | 0.997 |
| Missing values (%) | 22 (3.5) | 3 (7.0) | 19 (3.3) | |
| SIJ radiographs, mNY grading, 0–8 | 1.3 (1.6) | 1.1 (1.4) | 0.3 (1.7) | 0.695 |
| Missing values (%) | 19 (3.1) | 1 (2.3) | 18 (3.1) | |
| NSAID score in last week, 0–400 | 56.3 (52.3) | 73.5 (53.0) | 56.3 (52.3) | 0.021 |
| Steroid use | 72, 12% | 6, 14% | 66, 11% | 0.619 |
| TNFi use | 0, 0% | 0, 0% | 0, 0% | – |
Mean (SD) for continuous variables; n, % for categorical variables. N number reported where there were missing data for the specific variable.
*Comparisons between the Ever sick leave versus the Never sick leave categories were undertaken using the Wilcoxon test for continuous variables and either the χ2 or Fisher's exact test for categorical variables.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein; HLA-B27, Human Leukocyte Antigen B27; IBD, inflammatory bowel disease; mNY, modified New York; NSAIDs, non-steroidal anti-inflammatory drugs; SIJ, sacroiliac joints; SPARCC, Spondyloarthritis Research Consortium of Canada scoring system; TNFi, tumour necrosis factor inhibitor.
Effect of socioeconomic factors and clinical variables on sick leave in separate models for ASDAS (main model), BASFI and BASMI
| Multivariable model | Main model | Model with a focus on BASFI | Model with a focus on BASMI |
| HR (95% CI) | HR (95% CI) | HR (95% CI) | |
| Age | 1.05 (1.01 to 1.09) | 1.04 (1.00 to 1.08) | 1.04 (1.00 to 1.09) |
| Male gender | 0.41 (0.20 to 0.86) | 0.36 (0.18 to 0.75) | 0.35 (0.15 to 0.82) |
| High education | 0.48 (0.24 to 0.95) | 0.37 (0.19 to 0.72) | 0.42 (0.19 to 0.94) |
| ASDAS (CRP) | 1.49 (1.04 to 2.13) | * | * |
| BASFI, 0–10 | * | 1.05 (0.91 to 1.23) | * |
| BASMI, 0–10 | * | * | 1.36 (0.96 to 1.93) |
| Smoking (current vs not) | 2.55 (1.32 to 4.91) | 2.57 (1.35 to 4.89) | 2.71 (1.26 to 5.84) |
| Oral corticosteroid use (vs no) | – | 3.00 (1.34 to 6.69) | – |
| TNFi use | 2.41 (1.27 to 4.58) | 2.07 (1.07 to 4.01) | 2.55 (1.20 to 5.44) |
The symbol '*' denotes that the specific variables were not tested in the models; the symbol '-' denotes that the specific variables were not significant in the models.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein; TNFi, tumour necrosis factor inhibitor.